English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe results of a study published today in Nature Medicine show exciting immune responses in patients with operable esophageal or gastroesophageal cancers given neoadjuvant immunotherapy. The study results also show the potential for monitoring circulating tumor DNA as a predictor for future intervention.
Tag: Immunotherapy Clinical Trials
First New Jersey Patient Treated with Genetically Modified T-Cells Developed at state’s only National Cancer Institute-designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey has treated its first patient using genetically modified T-cells that were manufactured in its own state-of-the-art Good Manufacturing Practices (GMP) facility.
Chula Makes Progress in “CAR T-Cell Therapy” Innovation: New Hope for Thai Lymphoma Cancer Patients
Chulalongkorn University, Thailand, and Nagoya University, Japan, in their collaboration to develop an immunotherapy method for curing cancer, reported on the progress of CAR T-cell immunotherapy innovation for treating cancer in leukemia and B-cell lymphoma patients, which can increase survival rates and reduce cancer recurrence.
Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer
A combination treatment that targets the immune system helps treat aggressive prostate cancers that don’t respond to conventional therapies.
Dogs inhale immunotherapy to test lung cancer treatment
An inhaled immunotherapy successfully treated cancer in some companion dogs as part of a clinical trial conducted by UC Davis oncology and veterinary researchers. Recently published study results show potential for fighting cancer in humans as well.
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with advanced prostate cancer.
Study Shows Promise for Non-Small Cell Lung Cancer Patients Who Require New Treatment Options
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System. Early results appear promising in this phase 1/2 clinical trial of ADXS-503 being developed by Advaxis, Inc., a new type of cancer therapy which targets “hotspot” mutations that commonly occur in specific cancer types, both by itself and in combination with immunotherapy Keytruda® (pembrolizumab), which is commonly used to treat this type of lung cancer. Dr. Haigentz and colleagues published early results of this study in conjunction with ASCO 2020, the world’s premier scientific meeting for clinical research in oncology.